As we identified ERBB2 as a relevant pathway that mediates the expression of MHC-I and thereby antigen presentation in SCLC, we further investigated the impact of ERBB2 expression in SCLC patients with high tumor mutational burden (TMB). The gene discussed is ERBB2; the disease is neoplasm.